Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
One of the most urgent requirements in prostate cancer diagnosis is the development of a blood-based test which would be able to distinguish prostate cancer from benign prostate hyperplasia (BPH). Previously published results found a significant difference between specific glycan levels in patients with advanced prostate cancer and healthy controls. N-Glycans from the whole serum glycoproteins were measured using our fully quantitative high-throughput N-glycan analysis in combination with exoglycosidase digestions in sera from 13 BPH and 34 prostate cancer samples (17 Gleason score 5 and 17 Gleason score 7). The levels of core-fucosylated biantennary glycans and α2-3-linked sialic acids were significantly increased in prostate cancer patients compared with patients with BPH. Triantennary trigalactosylated glycans and tetraantennary tetrasialylated glycans with outer arm fucose were significantly decreased, and tetraantennary tetrasialylated glycans increased in Gleason 7 compared with Gleason 5. All these glycans can distinguish prostate cancer patients from BPH or Gleason 7 from Gleason 5 prostate cancer patients better than the current clinical test, prostate-specific antigen; therefore, their measurement may provide a new noninvasive approach to diagnose prostate cancer. However, additional validation studies would need to be carried out to further support this finding. Decreases in triantennary trigalactosylated glycans and/or bisected core-fucosylated biantennary monosialylated glycans and increases in tetraantennary tetrasialylated glycans correlate with perineural invasion, which could further help to diagnose tumor spread and predict patients' survival.
Saldova
Radka
R
Dublin-Oxford NIBRT Glycobiology Laboratory, NIBRT, Conway Institute, Dublin, Ireland.
Fan
Yue
Y
Fitzpatrick
John M
JM
Watson
R William G
RW
Rudd
Pauline M
PM
D002240:Carbohydrate Sequence; D003937:Diagnosis, Differential; D005643:Fucose / Q000032:analysis; D006026:Glycoside Hydrolases / Q000378:metabolism; D006031:Glycosylation; D057166:High-Throughput Screening Assays; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D011134:Polysaccharides / Q000032:analysis; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D044967:Serum / Q000737:chemistry; D012794:Sialic Acids / Q000032:analysis
D011134:Polysaccharides; D012794:Sialic Acids; D005643:Fucose; D006026:Glycoside Hydrolases; D017430:Prostate-Specific Antigen